Dupilumab (Dupixent)

Clinical evidence suggests that Dupixent should be reimbursed to treat patients aged 12 years and older with severe asthma and with a type 2 or eosinophilic phenotype or oral corticosteroid–dependent asthma. Economic evidence suggests that a 93% price reduction is needed to ensure Dupixent is cost-effective at a $50,000 per quality-adjusted life-year threshold relative to standard of care alone. Cost-effectiveness versus other biologics is unknown. CADTH was unable to estimate the budget impact due to a high degree of uncertainty.